Search

Your search keyword '"Proteases -- Planning"' showing total 13 results
Start Over Descriptor "Proteases -- Planning"
13 results on '"Proteases -- Planning"'

1. Omeros IND for OMS906 cleared by FDA

Subjects
Clinical trials, Monoclonal antibodies, Proteases -- Planning, Company business planning, Business, News, opinion and commentary
Abstract

Omeros said in a release, 'Omeros Corporation today announced that its Investigational New Drug Application, or IND, to begin clinical trials with OMS906 has been cleared by the FDA. OMS906 [...]

Published
2020

2. Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company

Subjects
Novo Nordisk A/S -- Officials and employees, Executives -- Planning, Proteases -- Planning, Blood coagulation factors -- Planning, Hemophilia, Pharmaceutical industry -- Officials and employees, Company business planning, Business, international, Law
Abstract

(GlobeNewswire) - Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has promoted Grant Blouse, Ph.D., to chief scientific officer and Tom Knudsen, DVM, Ph.D., to senior vice president, corporate development. [...]

Published
2021

3. Omeros Investigational New Drug Application for OMS906 Cleared by FDA

Subjects
United States. Food and Drug Administration -- Planning, Monoclonal antibodies, Proteases -- Planning, Biological products -- Planning, Company business planning, Business, international, Law
Abstract

Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). OMS906 is [...]

Published
2020

4. Selva raises $3m to develop novel antiviral against Covid-19

Subjects
Sofosbuvir -- Planning, Proteases -- Planning, COVID-19, Company business planning, Company financing, Business, international, Law
Abstract

Selva is planning to use the $3m it has raised in a Series A round to support the early clinical development of its lead candidate SLV213 for Covid-19. SLV213 is [...]

Published
2020

8. Omeros Updates on Investigational NDA for OMS906 Cleared by FDA

Subjects
United States. Food and Drug Administration -- Planning, Monoclonal antibodies, Proteases -- Planning, Company business planning, Business, Business, international, Telecommunications industry
Abstract

Omeros Corp. reported that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). According to a [...]

Published
2020

9. Cortexyme gathers $76M to fund efficacy study of antibiotic for Alzheimers

Subjects
Pfizer Inc. -- Officials and employees -- Planning, Bacterial infections, Antibiotics -- Planning, Protease inhibitors -- Planning, Proteases -- Planning, Pharmaceutical industry -- Officials and employees -- Planning, Alzheimer's disease, Company business planning, Business, international
Abstract

Alzheimers disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field. The [...]

Published
2018

10. Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency

Subjects
United States. Food and Drug Administration -- Planning, Business planning, Monoclonal antibodies, Proteases -- Planning, Company business planning, General interest, News, opinion and commentary, European Union -- Planning
Abstract

Seattle: Omeros Corporation has issued the following press release: Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with [...]

Published
2016

11. Q1 2011 Roche Holding AG Sales Conference Call - Final

Subjects
Protease inhibitors -- Planning, Medical research, Rheumatoid factor, Proteases -- Planning, Papillomavirus infections -- Care and treatment, Lung cancer -- Care and treatment, Blood sugar, Medical care, Cost of, Medicine, Experimental, Medicare -- Planning, Metastasis -- Care and treatment, Sugars, Stomach cancer -- Care and treatment, Angiogenesis inhibitors, Chief financial officers -- Planning, Boats and boating, Ovarian cancer -- Care and treatment, Rheumatoid arthritis -- Care and treatment, Company securities, Company business planning, Business
Abstract

Presentation SEVERIN SCHWAN, CEO, ROCHE HOLDING AG: Good afternoon, ladies and gentlemen. Welcome to our conference call. This is Severin Schwan speaking. With me in the room is Pascal Soriot, [...]

Published
2011

12. Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final

Subjects
Vertex Pharmaceuticals Inc. -- Planning, Interferon -- Planning, Protease inhibitors -- Dosage and administration -- Planning, Medical research, Medicine, Experimental, Financial analysts -- Planning, Proteases -- Planning, Financial markets, Drug therapy, Combination, Biological response modifiers, Securities offerings, Hepatitis C -- Care and treatment, Pharmaceutical industry -- Planning, Company business planning, Business
Abstract

PARTICIPANTS . Michael Partridge, Vertex Pharmaceuticals, Inc., Senior Director of Strategic Communications . Kurt Graves, Vertex Pharmaceuticals, Inc., EVP, Chief Commercial Officer, Head of Development . Freda Lewis-Hall, Vertex Pharmaceuticals, [...]

Published
2009

13. Medivir Announces Plans for a Phase II All-oral Study of Simeprevir (TMC435) and VX-135 for the Treatment of Hepatitis C to be Conducted by Janssen and Vertex

Subjects
Medivir AB -- Planning, Medical research, Medicine, Experimental, Protease inhibitors -- Planning, Proteases -- Planning, Hepatitis C virus, Pharmaceutical industry -- Planning, Company business planning, Business, News, opinion and commentary
Abstract

STOCKHOLM, November 1, 2012 /PRNewswire/ -- * Companies to evaluate a two-drug combination of Medivir/Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue VX-135 * Phase II proof-of-concept [...]

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results